LLY

806.49

-1.36%↓

UNH

558.26

-1.44%↓

JNJ

158.76

-0.76%↓

NVO

109.93

-1.8%↓

ABBV

202.01

-0.6%↓

LLY

806.49

-1.36%↓

UNH

558.26

-1.44%↓

JNJ

158.76

-0.76%↓

NVO

109.93

-1.8%↓

ABBV

202.01

-0.6%↓

LLY

806.49

-1.36%↓

UNH

558.26

-1.44%↓

JNJ

158.76

-0.76%↓

NVO

109.93

-1.8%↓

ABBV

202.01

-0.6%↓

LLY

806.49

-1.36%↓

UNH

558.26

-1.44%↓

JNJ

158.76

-0.76%↓

NVO

109.93

-1.8%↓

ABBV

202.01

-0.6%↓

LLY

806.49

-1.36%↓

UNH

558.26

-1.44%↓

JNJ

158.76

-0.76%↓

NVO

109.93

-1.8%↓

ABBV

202.01

-0.6%↓

Search

Bio-Rad Laboratories Inc

Suletud

Sektor Tervishoid

366.52 2.29

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

365.18

Max

370.53

Põhinäitajad

By Trading Economics

Sissetulek

2.8B

653M

Müük

11M

650M

Aktsiakasum

2.01

Kasumimarginaal

100.534

Töötajad

8,030

EBITDA

2.8B

107M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+7.4 upside

Turustatistika

By TradingEconomics

Turukapital

129M

11B

Eelmine avamishind

364.23

Eelmine sulgemishind

366.52

Uudiste sentiment

By Acuity

21%

79%

53 / 389 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Bio-Rad Laboratories Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. nov 2024, 22:50 UTC

Kuumad aktsiad

Stocks to Watch: Nvidia, Intel, Sherwin-Williams, Dow, Nuwellis

1. nov 2024, 22:43 UTC

Suurimad hinnamuutused turgudel

Nvidia, Sherwin-Williams Shares Up on Addition to DJIA

1. nov 2024, 22:13 UTC

Suurimad hinnamuutused turgudel

Chewy Up 5% on S&P MidCap 400 Inclusion

1. nov 2024, 21:39 UTC

Tulu

Insurance Company Chubb Projects Up to $300 Million Pre-Tax Loss on Hurricane

2. nov 2024, 13:53 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2. nov 2024, 13:44 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. nov 2024, 13:00 UTC

Tulu

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2. nov 2024, 12:58 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. nov 2024, 12:48 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2. nov 2024, 12:32 UTC

Tulu

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2. nov 2024, 12:28 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. nov 2024, 12:17 UTC

Tulu

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2. nov 2024, 12:00 UTC

Tulu

Berkshire Hathaway 3Q EPS $18272.00 >BRKA

2. nov 2024, 12:00 UTC

Tulu

Berkshire Hathaway 3Q BNSF Operating Earnings $1.38B >BRKA

2. nov 2024, 12:00 UTC

Tulu

Berkshire Hathaway 3Q Berkshire Hathaway Energy Company Operating Earnings $1.63B >BRKA

2. nov 2024, 12:00 UTC

Tulu

Berkshire Hathaway 3Q Insurance-Underwriting Operating Earnings $750M >BRKA

2. nov 2024, 12:00 UTC

Tulu

Berkshire Hathaway 3Q Other Operating Loss $877M >BRKA

2. nov 2024, 12:00 UTC

Tulu

Berkshire Hathaway 3Q Insurance-Investment Income Operating Earnings $3.66B >BRKA

2. nov 2024, 12:00 UTC

Tulu

Berkshire Hathaway 3Q Net $26.25B >BRKA

2. nov 2024, 12:00 UTC

Tulu

Berkshire Hathaway 3Q Other Controlled Businesses Operating Earnings $3.34B >BRKA

2. nov 2024, 12:00 UTC

Tulu

Berkshire Hathaway 3Q Non-Controlled Businesses Operating Earnings $199M >BRKA

2. nov 2024, 12:00 UTC

Tulu

Berkshire Hathaway 3Q Operating Earnings $10.09B >BRKA

2. nov 2024, 12:00 UTC

Tulu

Berkshire Hathaway 3Q Investment, Derivative Gains $16.16B >BRKA

2. nov 2024, 09:30 UTC

Peamised uudised

Awful Jobs Report Aside, the Economy Is Still Strong -- Heard on the Street -- WSJ

2. nov 2024, 08:20 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

2. nov 2024, 08:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

1. nov 2024, 22:51 UTC

Tulu

Correction to Nvidia to Replace Intel in Dow Jones Industrial Average Article -- WSJ

1. nov 2024, 22:00 UTC

Peamised uudised
Tulu

Nvidia to Replace Intel in Dow Jones Industrial Average. Sherwin-Williams Also Joins. -- WSJ

1. nov 2024, 21:29 UTC

Peamised uudised
Tulu

Exxon and Chevron Feel Brunt of Cheaper Oil -- 2nd Update

1. nov 2024, 21:24 UTC

Tulu

Insurance Company Chubb Projects Up to $300M Pre-Tax Loss on Hurricane

Võrdlus sarnastega

Hinnamuutus

Bio-Rad Laboratories Inc Prognoos

Hinnasiht

By TipRanks

7.4% tõus

12 kuu keskmine prognoos

Keskmine 395.67 USD  7.4%

Kõrge 469 USD

Madal 315 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Bio-Rad Laboratories Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

4

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

327.65 / N/AToetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

53 / 389 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.